Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin in Atrial Fibrillation
NCT02931253Phase 2Terminated
- Sponsor
- Guthrie
- Start
- Apr 2017
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of metformin in Atrial fibrillation (AFib) (2 arms), sponsored by Guthrie. Primary endpoint: Number of Participants Who Maintain Sinus Rhythm at 6 months. Started Apr 2017; status: terminated.
02
Drugs
metformin
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT02931253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02931253.